Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
Authors:
- Marianne Ulcickas YoodMYMarianne Ulcickas Yood
- Gerald N DeLorenzeGDGerald N DeLorenze
- Charles P QuesenberryJrCQCharles P QuesenberryJr
- Susan A OliveriaSOSusan A Oliveria
- Ai-Lin TsaiATAi-Lin Tsai
- Edward KimEKEdward Kim
- Mark J CzirakyMCMark J Cziraky
- Robert D McQuadeRMRobert D McQuade
- John W NewcomerJNJohn W Newcomer
- Gilbert J L'ItalienGLGilbert J L'Italien
Open Access
- 15 December 2011
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 11 (1) , 197
Abstract
Background: The benefits of some second-generation antipsychotics (SGAs) must be weighed against the increased risk for diabetes mellitus. This study examines whether the association between SGAs and diabetes differs by dose. Methods: Patients were ≥18 years of age from three US healthcare systems and exposed to an SGA for ≥45 days between November 1, 2002 and March 31, 2005. Patients had no evidence of diabetes before index date and no previous antipsychotic prescription filled within 3 months before index date. 49,946 patients were exposed to SGAs during the study period. Person-time exposed to antipsychotic dose (categorized by tertiles for each drug) was calculated. Newly treated diabetes was identified using pharmacy data to determine patients exposed to anti-diabetic therapies. Adjusted hazard ratios for diabetes across dose tertiles of SGA were calculated using the lowest dose tertile as reference. Results: Olanzapine exhibited a dose-dependent relationship for risk for diabetes, with elevated and progressive risk across intermediate (diabetes rate per 100 person-years = 1.9; adjusted Hazard Ratio (HR), 1.7, 95% confidence interval (CI), 1.0-3.1) and top tertile doses (diabetes rate per 100 person-years = 2.7; adjusted HR, 2.5, 95% CI, 1.4-4.5). Quetiapine and risperidone exhibited elevated risk at top dose tertile with no evidence of increased risk at intermediate dose tertile. Unlike olanzapine, quetiapine, and risperidone, neither aripiprazole nor ziprasidone were associated with risk of diabetes at any dose tertile. Conclusions: In this large multi-site epidemiologic study, within each drug-specific stratum, the risk of diabetes for persons exposed to olanzapine, risperidone, and quetiapine was dose-dependent and elevated at therapeutic doses. In contrast, in aripiprazole-specific and ziprasidone-specific stratum, these newer agents were not associated with an increased risk of diabetes and dose-dependent relationships were not apparent. Although, these estimates should be interpreted with caution as they are imprecise due to small numbers.Keywords
This publication has 14 references indexed in Scilit:
- Treatment with antipsychotics and the risk of diabetes in clinical practiceThe British Journal of Psychiatry, 2010
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia PatientsNeuropsychopharmacology, 2010
- Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care SystemPsychiatric Services, 2009
- The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic studyPharmacoepidemiology and Drug Safety, 2009
- Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorderSchizophrenia Research, 2009
- The Influence of Study Design on the Results of Pharmacoepidemiologic Studies of Diabetes Risk With Antipsychotic TherapyAnnals of Clinical Psychiatry, 2006
- Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesThe Journal of Clinical Psychiatry, 2004
- Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesDiabetes Care, 2004
- A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United StatesJournal of Clinical Epidemiology, 2003
- The Risk of Diabetes During Olanzapine Use Compared With Risperidone UseThe Journal of Clinical Psychiatry, 2002